These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37579382)

  • 1. Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic.
    Eren Vural I; Herder M; Doll A; Graham JE
    Int J Health Policy Manag; 2023; 12():6936. PubMed ID: 37579382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pandemics, intellectual property and 'our economy': A worldview analysis of Canada's role in compromising global access to COVID-19 vaccines.
    Brisbois B; Plamondon K; Walugembe D; Pereira RC; Edet C; Dixon J; Habibi R; Karamouzian M; Labonté R; Murthy S; Ravitsky V
    Glob Public Health; 2024 Jan; 19(1):2335360. PubMed ID: 38626321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canada and the pharmaceutical industry in the time of COVID-19.
    Lexchin J
    Int J Soc Determinants Health Health Serv; 2023 Oct; 53(4):508-517. PubMed ID: 37574784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator.
    Saxena A; Baker BK; Banda A; Herlitz A; Miller J; Karrar K; Fleurbaey M; Chiwa E; Atuire CA; Hirose I; Hassoun N
    BMJ Glob Health; 2023 Jan; 8(1):. PubMed ID: 36650015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US public investment in development of mRNA covid-19 vaccines: retrospective cohort study.
    Lalani HS; Nagar S; Sarpatwari A; Barenie RE; Avorn J; Rome BN; Kesselheim AS
    BMJ; 2023 Mar; 380():e073747. PubMed ID: 36858453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19.
    Yu H
    Inquiry; 2021; 58():469580211059734. PubMed ID: 34855535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharma innovation trends during COVID-19 and beyond: an evidence from global partnerships and fundraising activities, 2011-2022.
    Yu TH; Mei YY; Tseng YJ
    Global Health; 2023 Aug; 19(1):57. PubMed ID: 37580752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How much do the public sector and the private sector contribute to biopharmaceutical R&D?
    Simoens S; Huys I
    Drug Discov Today; 2022 Apr; 27(4):939-945. PubMed ID: 34863932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sticking to the knitting: CIHR, innovation and Canadian biotech.
    Edelson J
    Healthc Q; 2005; 8(3):65-8. PubMed ID: 16078405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing development of medical countermeasures: Incorporating COVID-19 lessons learned into future pandemic preparedness planning.
    Johnson RA; White RC; Disbrow GL
    Hum Vaccin Immunother; 2022 Nov; 18(6):2129930. PubMed ID: 36302122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadians' opinions towards COVID-19 data-sharing: a national cross-sectional survey.
    Savic Kallesoe SA; Rabbani T; Gill EE; Brinkman F; Griffiths EJ; Zawati M; Liu H; Palmour N; Joly Y; Hsiao WWL
    BMJ Open; 2023 Feb; 13(2):e066418. PubMed ID: 36750286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COVID-19 Innovation System.
    Sampat BN; Shadlen KC
    Health Aff (Millwood); 2021 Mar; 40(3):400-409. PubMed ID: 33539184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Funding Sources of Therapeutic and Vaccine Clinical Trials for COVID-19 vs Non-COVID-19 Indications, 2020-2021.
    Angelis A; Suarez Alonso C; Kyriopoulos I; Mossialos E
    JAMA Netw Open; 2022 Aug; 5(8):e2226892. PubMed ID: 35972740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic.
    Tietze F; Vimalnath P; Aristodemou L; Molloy J
    IEEE Trans Eng Manag; 2022 Oct; 69(5):2039-2056. PubMed ID: 35938060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Canada Pension Plan's experience with investing its portfolio in equities.
    Sarney M; Preneta AM
    Soc Secur Bull; 2001-2002; 64(2):46-56. PubMed ID: 12428509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Strategic National Stockpile: identification, support, and acquisition of medical countermeasures for CBRN incidents.
    Neumeister SM; Gray JP
    Toxicol Mech Methods; 2021 May; 31(4):308-321. PubMed ID: 33208007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving toward a common goal via cross-sector collaboration: lessons learned from SARS to COVID-19 in Singapore.
    Kim S; Goh Y; Kang JHB
    Global Health; 2022 Sep; 18(1):82. PubMed ID: 36131348
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.